Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bioxyne Limited ( (AU:BXN) ) has shared an announcement.
Bioxyne Limited has upgraded its full-year FY2025 revenue guidance to $28 million, reflecting significant growth driven by its Australian pharmaceutical manufacturing and supply operations. The company reported a 267% increase in revenue for the first half of FY2025 and anticipates continued expansion in FY2026, particularly in Australia, the UK, Germany, and other EU markets. Bioxyne’s subsidiary, Breathe Life Sciences, leads the Australian market in manufacturing medicinal cannabis, MDMA, and Psilocybin products, contributing to the company’s robust performance. The company is also advancing its MDMA capsules into commercial production, positioning itself for long-term success in the growing psychedelic drugs market.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical company focused on developing and commercializing innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.
Average Trading Volume: 2,799,237
Technical Sentiment Signal: Buy
Current Market Cap: A$56.29M
For an in-depth examination of BXN stock, go to TipRanks’ Stock Analysis page.